Hybio Pharmaceutical マネジメント

マネジメント基準チェック /34

現在、CEO に関する十分な情報がありません。

主要情報

Yu Pinxiang

最高経営責任者

CN¥1.8m

報酬総額

CEO給与比率	n/a
CEO在任期間	5.5yrs
CEOの所有権	0.06%
経営陣の平均在職期間	3.1yrs
取締役会の平均在任期間	4.7yrs

経営陣の近況

Recent updates

Investor Optimism Abounds Hybio Pharmaceutical Co., Ltd. (SZSE:300199) But Growth Is Lacking

Sep 30

Here's Why Hybio Pharmaceutical (SZSE:300199) Can Afford Some Debt

Jul 20

Hybio Pharmaceutical Co., Ltd.'s (SZSE:300199) Price Is Out Of Tune With Revenues

Jun 03

Hybio Pharmaceutical Co., Ltd.'s (SZSE:300199) 27% Share Price Surge Not Quite Adding Up

Feb 29

Is Hybio Pharmaceutical (SZSE:300199) Using Too Much Debt?

Feb 26

CEO（最高経営責任者

Yu Pinxiang (51 yo)

5.5yrs

在職期間

CN¥1,842,600

報酬

Ms. Pinxiang Yu serves as Director of Hybio Pharmaceutical Co., Ltd. since May 31, 2019 and serves as its Executive President. She served as a Vice President of Production Department at Hybio Pharmaceutica...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Yu Pinxiang	Executive President & Director	no data	CN¥1.84m	0.060% CN¥ 6.1m
Honghong Tu	VP, CFO & Accounting Supervisor	3.3yrs	CN¥649.80k	データなし
Di Yang	VP, Secretary & Director	2.8yrs	CN¥781.00k	データなし
Zhaohui Zeng	Vice President	3.3yrs	CN¥1.19m	データなし
Min Zhang	Vice President	2.9yrs	CN¥616.50k	データなし
Heng Quan	Vice President of Human Resource & Administration Department	no data	CN¥840.50k	データなし
Yu Liu	Vice President of Marketing	no data	CN¥398.30k	データなし

3.1yrs

平均在職期間

48yo

平均年齢

経験豊富な経営陣: 300199の経営陣は経験豊富であると考えられます ( 3.1年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Yu Pinxiang	Executive President & Director	5.5yrs	CN¥1.84m	0.060% CN¥ 6.1m
Di Yang	VP, Secretary & Director	4.6yrs	CN¥781.00k	データなし
Lian Zhong	Independent Director	3.3yrs	CN¥60.00k	データなし
Shaobin Zeng	Non-Independent Director	4.8yrs	CN¥65.70k	2.46% CN¥ 251.5m
Lu Yang	Member of Non-Employee Supervisory Board	2.9yrs	データなし	データなし
Qingyang Li	Chairman of Supervisory Board	5.5yrs	データなし	データなし
Yangming Tang	VP & Director	3.8yrs	CN¥976.90k	データなし
Wenyan Hu	Independent Director	2.9yrs	CN¥120.00k	データなし
Shaoqiang Zeng	Vice Chairman	15yrs	CN¥60.10k	8.15% CN¥ 833.6m
Shaogui Zeng	Chairman	15yrs	CN¥1.12m	12.41% CN¥ 1.3b
Lin Liang	Supervisor	no data	データなし	データなし

4.7yrs

平均在職期間

48yo

平均年齢

経験豊富なボード: 300199の取締役会は経験豊富であると考えられます ( 4.7年の平均在任期間)。

Hybio Pharmaceutical マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Hybio Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

Hybio Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: CN¥0.045 loss per share (vs CN¥0.15 loss in 3Q 2023)

Hybio Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Investor Optimism Abounds Hybio Pharmaceutical Co., Ltd. (SZSE:300199) But Growth Is Lacking

Second quarter 2024 earnings released: EPS: CN¥0.003 (vs CN¥0.068 loss in 2Q 2023)

Here's Why Hybio Pharmaceutical (SZSE:300199) Can Afford Some Debt

Hybio Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024

Hybio Pharmaceutical Co., Ltd.'s (SZSE:300199) Price Is Out Of Tune With Revenues

Hybio Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

First quarter 2024 earnings released: CN¥0.02 loss per share (vs CN¥0.02 profit in 1Q 2023)

Hybio Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

Hybio Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Hybio Pharmaceutical Co., Ltd.'s (SZSE:300199) 27% Share Price Surge Not Quite Adding Up

Is Hybio Pharmaceutical (SZSE:300199) Using Too Much Debt?

Hybio Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024

Third quarter 2023 earnings released: CN¥0.15 loss per share (vs CN¥0.05 loss in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.068 loss per share (vs CN¥0.049 loss in 2Q 2022)

Hybio Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 15, 2023

First quarter 2023 earnings released: EPS: CN¥0.02 (vs CN¥0.06 loss in 1Q 2022)

High number of new and inexperienced directors

Third quarter 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.096 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.049 loss per share (vs CN¥0.058 loss in 2Q 2021)

Hybio Pharmaceutical Co., Ltd. (SZSE:300199) agreed to acquire 10.81% stake in Hybio Biotechnology (Dali) Co., Ltd. from Dazhong Transportation (Group) Co., Ltd. (SHSE:600611) for CNY 20 million.

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

High number of new and inexperienced directors

Third quarter 2021 earnings released: CN¥0.096 loss per share (vs CN¥0.009 profit in 3Q 2020)

Less than half of directors are independent

First quarter 2021 earnings released: EPS CN¥0.026 (vs CN¥0.025 in 1Q 2020)

Hybio Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Apr 23, 2021

New 90-day low: CN¥5.60

New 90-day low: CN¥6.66

New 90-day low: CN¥7.17

New 90-day low: CN¥7.43

Third quarter earnings released

Hybio Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020

First half earnings released

New 90-day high - CN¥7.95

Hybio Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 14, 2020

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34